Werewolf Therapeutics, Inc. (HOWL) Misses Q2 EPS by 23c

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of ($0.53), $0.23 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $4.15 million versus the consensus estimate of $3.75 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Alto Neuroscience, Inc. (ANRO) Tops Q2 EPS by 10c
• FGI Industries Ltd (FGI) Tops Q2 EPS by 59c